Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients.

Xu TY, Zhang Y, Li Y, Zhu DL, Gao PJ.

Ren Fail. 2014 Jun;36(5):666-72. doi: 10.3109/0886022X.2014.890002. Epub 2014 Feb 27.

PMID:
24575880
2.
3.

Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.

Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca L, Piechota M, Baj Z.

Int Urol Nephrol. 2011 Jun;43(2):491-8. doi: 10.1007/s11255-009-9683-1. Epub 2009 Dec 2.

PMID:
19953348
4.

Not all inflammatory markers are linked to kidney function: results from a population-based study.

Pruijm M, Ponte B, Vollenweider P, Mooser V, Paccaud F, Waeber G, Marques-Vidal P, Burnier M, Bochud M.

Am J Nephrol. 2012;35(3):288-94. doi: 10.1159/000335934. Epub 2012 Mar 6.

PMID:
22398717
5.
6.

Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in blood as markers for early atherosclerosis in subjects with chronic periodontitis.

Söder PO, Meurman JH, Jogestrand T, Nowak J, Söder B.

J Periodontal Res. 2009 Aug;44(4):452-8. doi: 10.1111/j.1600-0765.2008.01145.x. Epub 2008 Oct 22.

PMID:
18973519
7.

Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.

Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF.

Endothelium. 2006 May-Jun;13(3):227-31.

PMID:
16840178
8.

Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation.

Kalogeropoulos AS, Tsiodras S, Rigopoulos AG, Sakadakis EA, Triantafyllis A, Kremastinos DT, Rizos I.

BMC Cardiovasc Disord. 2011 Dec 28;11:77. doi: 10.1186/1471-2261-11-77.

9.

Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage.

Morillas P, Quiles J, de Andrade H, Castillo J, Tarazón E, Roselló E, Portolés M, Rivera M, Bertomeu-Martínez V.

J Hypertens. 2013 Aug;31(8):1611-7. doi: 10.1097/HJH.0b013e3283614c1c.

PMID:
23615327
10.

Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria.

Pulido-Olmo H, García-Prieto CF, Álvarez-Llamas G, Barderas MG, Vivanco F, Aranguez I, Somoza B, Segura J, Kreutz R, Fernández-Alfonso MS, Ruilope LM, Ruiz-Hurtado G.

Clin Sci (Lond). 2016 Apr 1;130(7):525-38. doi: 10.1042/CS20150517. Epub 2016 Jan 5.

PMID:
26733721
11.

Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation.

Lee ES, Shen Q, Pitts RL, Guo M, Wu MH, Sun SC, Yuan SY.

J Vasc Surg. 2011 Aug;54(2):454-9; discussion 459-60. doi: 10.1016/j.jvs.2011.02.056. Epub 2011 May 28.

12.

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.

Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.

Circulation. 2006 May 2;113(17):2089-96. Epub 2006 Apr 24.

13.

Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.

Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ.

Am J Cardiol. 2005 Aug 1;96(3):339-45.

PMID:
16054454
14.
15.

Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.

Anticancer Res. 2000 Mar-Apr;20(2B):1311-6.

PMID:
10810441
16.

Evaluation of systemic levels of neutrophilic enzymes in patients with hypertension and chronic periodontitis.

Türkoğlu O, Barış N, Tervahartiala T, Şenarslan Ö, Sorsa T, Atilla G.

J Periodontol. 2014 Jul;85(7):908-16. doi: 10.1902/jop.2013.130346. Epub 2013 Nov 14.

PMID:
24224962
17.

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.

Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blanquer J, Orbe J, Rodríguez JA, Jiménez A, Borreguero-León JM, Belmonte F, Medina JC, Llimiñana MC, Ferrer-Agüero JM, Ferreres J, Mora ML, Lubillo S, Sánchez M, Barrios Y, Sierra A, Páramo JA.

Crit Care. 2009;13(5):R158. doi: 10.1186/cc8115. Epub 2009 Oct 2.

18.

Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis.

Palus M, Zampachová E, Elsterová J, Růžek D.

J Infect. 2014 Feb;68(2):165-9. doi: 10.1016/j.jinf.2013.09.028. Epub 2013 Oct 1.

PMID:
24091083
19.

In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.

Giansante C, Fiotti N, Di Chiara A, Altamura N, Wasserman S, Fioretti P, Guarnieri G.

J Cardiovasc Med (Hagerstown). 2007 Aug;8(8):602-7.

PMID:
17667031
20.

Markers of increased cardiovascular risk in patients with chronic kidney disease.

Gluba-Brzózka A, Michalska-Kasiczak M, Franczyk-Skóra B, Nocuń M, Banach M, Rysz J.

Lipids Health Dis. 2014 Aug 21;13:135. doi: 10.1186/1476-511X-13-135.

Items per page

Supplemental Content

Write to the Help Desk